BioPharma Leader’s Journey From Narcan to NervGen

Read Time:3 Minute, 3 Second

INTERVIEW ON THE PRICE OF BUSINESS SHOW, MEDIA PARTNER OF THIS SITE.

Recently Kevin Price, Host of the nationally syndicated Price of Business Show, interviewed Mike Kelly.

Kevin Price, host of the nationally syndicated Price of Business show, interviews Mike Kelly, President & CEO at NervGen Pharma on the anniversary of his first year at the company.  In April 2023, Philadelphia-based, Mike Kelly took the reins as CEO at NervGen Pharma (TSXV: NGEN) (OTC: NGENF) a clinical stage biotech company focused on developing treatments for spinal cord injuries. Kelly is leading the 6-year-old organization on its path to commercialize the company’s lead drug candidate, a first-in-class neuroreparative therapeutic.

On the Price of Business, Kelly talked about the landmark clinical trial for NVG-291 for chronic and subacute spinal cord injury (SCI) patients at the Shirley Ryan AbilityLab in Chicago.

Kelly, whose career began at TAP Pharmaceuticals (Takeda), has had successful runs through a series of smaller biopharma organizations, including eight years at Azur Pharma, most recently as President of US Operations where he played a key role in the development and commercialization of NARCAN (naloxone HCI) Nasal Spray in the US and Canada and in the eventual sale to Emergent BioSolutions for $735M.

NervGen’s innovation is focused on commercializing the groundbreaking research and tenacious perseverance of a single researcher, Dr. Jerry Silver, Professor of Neurosciences at Case Western Reserve University’s School of Medicine and adjunct Professor in the Department of Neurosurgery at the Cleveland Clinic Foundation, who overturned nearly a century of neuroscience precedence. The research community’s understanding of CNS injury and repair was turned on its head with the discovery and development of a new drug (NVG-291), licensed to NervGen in 2018. Dr. Silver has spent decades exploring ways to restore function for individuals with spinal cord injuries. He and his research team achieved an unprecedented breakthrough (Nature:13 July 2011) in spurring repair of the nervous system in preclinical models in the development of NVG-291. Dr. Silver has received numerous prestigious awards, including the Ameritec Prize, the Christopher Reeve-Joan Irvine Research Medal, and the Jacob Javits Neuroscience Investigator Award.

Recognized as a Top 50 TSX Venture Company, the company is on track to complete enrollment to deliver the data readout in Q3 2024 of the chronic cohort in the company’s Phase 1b/2a proof-of-concept, double blind, randomized placebo-controlled clinical trial for its proprietary investigational lead compound, NVG-291, in individuals with SCI.

Last fall the company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its proprietary lead compound, NVG-291, in individuals with spinal cord injury (SCI). FDA’s Fast Track program is designed to facilitate the development of drugs intended to treat serious conditions and fill unmet medical needs as part of the FDA’s goal to get important new drugs to patients earlier.

Doug Roland, an Oscar nominated social impact filmmaker telling stories about individuals and communities underrepresented and overlooked, completed a film short on NervGen Pharma which can be seen here.

 

 

For more business-related stories click here.

LISTEN TO THE INTERVIEW IN ITS ENTIRETY HERE:

The Price of Business is one of the longest running shows of its kind in the country and is in markets coast to coast. The Host, Kevin Price, is a multi-award winning author, broadcast journalist, and syndicated columnist. Learn more about the show and its digital partners at www.PriceofBusiness.com (scroll down to the bottom of the page).

About Post Author

US Daily Review News

No articles on this site should be construed as the opinion of PriceofBusiness.com. Do your homework, get expert advice before following the advice on this or any other site.
Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Videos